MEDICAL RISK CLASSIFICATION FOR SEVERE COVID-19 BASED ON 1

CHRONIC MEDICAL CONDITIONS: A COMPARATIVE ANALYSIS 2

3

3490 words

4 5 6	Ilse Westerhof ^{1*} , Annemarijn de Boer ¹ , Angela Lupattelli ² , Isabel Slurink ¹ , Otilia Boldea ³ , Hedvig Marie Egeland Nordeng ^{2,4} , Jizzo R. Bosdriesz ^{5,6,7} , Frank Pijpers ^{8,9} , Maarten Schim van der Loeff ^{5,6,7} , Mirjam Knol ⁵ , Janneke van de Wijgert ^{1,5} , Patricia Bruijning ¹ , and Ganna Rozhnova ^{1,10,11,12}
7	¹ Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, The
8	Netherlands
9	² Pharmacoepidemiology and Drug Safety Research group, Department of Pharmacy, University of Oslo, Oslo, Norway
10	³ Department of Econometrics and OR, Tilburg School of Economics and Management, Tilburg University, Tilburg, The
11	Netherlands
12	⁴ Department of Child Health and Development, National Institute of Public Health, Oslo, Norway
13	⁵ Department of Infectious Disease Control, National Institute for Diseases, Public Health and the Environment, Bilthoven
14	⁶ Amsterdam UMC location University of Amsterdam, Infectious Diseases, Meibergdreef 9, Amsterdam, the Netherlands
15	⁷ Amsterdam institute for Immunology & Infectious Diseases, Amsterdam, the Netherlands
16	⁸ Statistics Netherlands, The Hague, Netherlands
17	⁹ Korteweg-de Vries Institute for Mathematics, University of Amsterdam, Amsterdam, The Netherlands
18	¹⁰ Center for Complex Systems Studies (CCSS), Utrecht University, Utrecht, The Netherlands
19	¹¹ BioISI—Biosystems & Integrative Sciences Institute, Faculdade de Ciências, University of Lisbon, Lisbon, Portugal
20	¹² Faculdade de Ciências, University of Lisbon, Lisbon, Portugal
21	*Corresponding author: Ilse Westerhof; i.westerhof-4@ucmutrecht.nl

22

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 Abstract (299 words)

24	Background: The European Centre for Disease Prevention and Control (ECDC) provides listings of
25	medical conditions conferring high- or moderate-risk for severe COVID-19. In addition, individual
26	European countries developed their own risk classifications for severe COVID-19 to select individuals
27	recommended for annual COVID-19 vaccination. We assessed the discordance between the European and
28	respective national medical risk classifications in assigning children and adults to risk groups for
29	developing severe COVID-19 in populations of the Netherlands and Norway.
30	Methods: This multi-country, healthcare data-linkage study covered 17.4 million inhabitants of the
31	Netherlands and 5.6 million inhabitants of Norway by 1 January 2020. Medical conditions were defined
32	based on ICD-10 hospital discharge codes in the European and Dutch classifications, and on ICD-10 and
33	ICPC-2 primary care codes in the Norwegian classification. Subjects were classified as high-, moderate-,
34	or low-risk. Discordance was calculated as the proportion of the population with a different risk status in
35	the respective national compared to the European classification.
36	Findings: The overall discordance between European and national risk classification was 12.0% in the
37	Dutch and 13.8% in the Norwegian population. The European classification assigns more individuals to
38	high-risk (9.0% and 9.2% of the Dutch and Norwegian populations, respectively) than the national
39	classifications (1.5% and 3.0%, respectively). National classifications define more individuals as
40	moderate-risk (11.3% and 12.7%, respectively) than the European classification (1.0% and 1.3%,
41	respectively). Classification discordances most frequently involved subjects with cardiovascular disease,
42	lung disease, and diabetes mellitus.
43	Interpretation: The European classification defines a substantially larger percentage of the population as
44	high-risk for severe COVID-19 than the national classifications. This may have implications for post-
45	pandemic vaccination programs. Further research should assess to what extent the medical conditions
46	responsible for the classification discordances determine the risk of developing severe COVID-19.
47	
48	Funding: ZonMw, EU, FCT, Norwegian Research Council's COVID-19 Emergency Call, iAPOGEE.

49 Research in context

- 50 Evidence before this study
- 51 We searched PubMed for English-language articles published from 1 January 2020 to 1 July 2024, using
- 52 the search terms (((("COVID-19"[Title] OR "SARS-CoV-2"[Title]) AND ("sever*"[Title] OR
- 53 "hospital*"[Title] OR "death"[Title] OR "decease*"[Title]) AND ("chronic condition*"[Title/Abstract] OR
- 54 "comorbidit*"[Title/Abstract]) AND ("guideline"[Title] OR "classification"[Title] OR "system"[Title])
- 55 AND 2020/01/01:2024/07/01[Date Create]) NOT "clinical trial"[Publication Type]) NOT "case
- 56 reports"[Publication Type]). This search identified 64 studies, but none of them assessed the impact of
- 57 different medical risk classifications for severe COVID-19 or compared them across countries or to the
- 58 European classification.
- 59

60 Added value of this study

- 61 To the best of our knowledge, this is the first study that compared the impact of European and national
- 62 medical risk classifications for severe COVID-19 by assigning the populations of the Netherlands and
- 63 Norway to medical risk groups using national healthcare registries. We demonstrated important
- 64 discrepancies between the European and respective national schemes in classifying high- and moderate-
- 65 risk individuals in both countries. The chronic conditions responsible for the classification discordances
- 66 were lung disease, cardiovascular disease, neurological disorders, diabetes mellitus, cancer, and
- 67 hypertension.
- 68

69 Implications of all the available evidence

70 Our comparative analysis suggests that the choice between the European and national classifications may

71 have important consequences for public health interventions such as vaccination campaigns. The

- variability in risk assignment based on chronic medical conditions underscores the absence of an
- 73 international uniform approach. More research is needed to determine the extent to which each chronic
- 74 medical condition impacts COVID-19 severity in the post-pandemic period, facilitating the refinement of
- 75 risk classifications and supporting targeted public health interventions.

76 Introduction

77	The impact of public health measures, including COVID-19 vaccination, depends on the accurate
78	identification of populations at elevated risk for severe outcomes, including hospitalization and death ¹ . The
79	World Health Organization recommends targeting vaccination programs to population groups at the
80	highest risk of severe COVID-19 ¹ , but disparities exist in the risk classifications developed by different
81	health authorities. While COVID-19 currently presents as common cold- or flu-like illness, older
82	individuals and those with certain chronic medical conditions still face higher hospitalization and death
83	rates compared to the general population ^{2,3} . Most risk classifications group individuals into high-,
84	moderate-, and low-risk for severe COVID-19, based on factors like medical conditions and age. High-risk
85	individuals have chronic conditions that lead to a much higher likelihood of severe outcomes, while those
86	in the moderate-risk group face an elevated but lower risk.
87	
88	Informed by influenza risk classifications and studies on risk factors for severe COVID-19, national (e.g.,
89	the Health Council of the Netherlands ⁴ and the Public Health Institute in Norway ⁵) and international (e.g.,
90	the European Centre for Disease Prevention and Control ⁶) public health authorities assigned high- or
91	moderate-risk of developing severe COVID-19 to specific pre-existing medical conditions. These medical
92	risk classifications have remained unchanged ^{6,7} or undergone minor alterations ^{4,5,8,9} since their
93	development at the beginning of the pandemic. They have continued to guide epidemiological research and
94	policy decisions on eligibility criteria and prioritization for vaccination programs aimed at reducing the
95	incidence of severe COVID-19. While these European and national classifications can be applied within
96	the same country, it is unclear to what extent they differ in assigning medical risk status to individuals.
97	
98	To inform evidence-based decision-making for severe COVID-19, we conducted a comparative analysis of
99	risk status in the respective national versus the European classification. This observational national
100	registry-based cohort study used Dutch and Norwegian health and administrative data from 1 January
101	2020, linked at the individual level, including 17.4 million inhabitants of the Netherlands and 5.6 million
102	inhabitants of Norway. We aimed to examine discordance between the respective national and European
103	medical risk classifications for severe COVID-19 and investigate related factors.

104 Methods

105 Data Collection

106 Data collection – The Netherlands

107 The Dutch dataset included hospital discharge registry (DHD) data for all inhabitants of the Netherlands as

108 per the Dutch Population Registry on 1 January 2020. The two registries were linked using unique personal

109 identification numbers. The Population Registry was used to extract age, immigration, and emigration

110 dates. The DHD provided information on chronic medical conditions diagnosed in hospitals since 1

111 January 1995, including the date of diagnosis. All diagnoses were registered according to the International

112 Statistical Classification of Diseases and Related Health Problems, 10th revision (ICD-10)¹⁰.

113

114 Data collection – Norway

115 The Norwegian dataset included data from multiple Norwegian registries for all inhabitants of Norway as

116 per the National Population Registry on 1 January 2020. The registries included the Statistics Norway

117 (SSB) registry, the Norwegian Patient Registry (NPR), and the Norway Control and Payment of Health

118 Reimbursements (KUHR) registry. These registries were linked using unique personal identification

119 numbers. The NPR and SSB registries were used to extract age, immigration, and emigration dates for all

120 inhabitants of Norway. The KUHR registry provided information on medical diagnoses in primary and

121 secondary outpatient care using the International Classification of Primary Care (ICPC-2/ICPC-2B) and

122 ICD-10 codes, respectively^{10,11}. The NPR provided information on medical diagnoses in specialist

123 outpatient and inpatient care, using ICD-10 coding. Both KUHR and NPR provided medical diagnosis data

- 124 since 1 January 2010.
- 125

126 Risk classifications for severe COVID-19

127 The Dutch risk classification was obtained from the 'Adviesnota Vaststelling volwassen medische

128 risicogroepen COVID-19-vaccinatiecampagne' ['Recommendation on establishing adult medical risk

129 groups for the COVID-19 vaccination campaign'] in February 2023⁴. This classification contains a list of

130 chronic medical condition categories defined as either high- or moderate-risk for severe COVID-19. Each

131 medical condition was independently coded using ICD-10 by two authors (AvB and IW), with no

132 discrepancies found.

133

134 The Norwegian risk classification was obtained from the Norwegian Health Institute in July 2023⁵. This 135 scheme includes chronic medical condition categories with corresponding ICPC-2 and ICD-10 codes 136 classified as either high-risk or increased-risk, which we renamed as high- and moderate-risk for 137 consistency with other classifications. 138 139 The European risk classification was obtained from the 'Core protocol for ECDC studies of COVID-19 140 vaccine effectiveness against hospitalization with Severe Acute Respiratory Infection (SARI), laboratory-141 confirmed with SARS-CoV-2 or with seasonal influenza – Version 3.0' dated February 2024⁶. This 142 protocol provides ICD-10 codes for medical condition categories that are mandatory or optional for

143 reporting in the ECDC studies. We classified the former medical condition categories as high-risk and the

144 latter as moderate-risk.

145

Individuals in the Dutch or Norwegian datasets were assigned to have moderate- or high-risk chronic
medical conditions if at least one relevant ICD-10 (both datasets) or ICPC-2 code (Norwegian cohort only)
was recorded for that individual within the six months prior to 1 January 2020. For cancer diagnoses,
records within five years prior to 1 January 2020 were used. Different medical risk classifications may use
different codes for the same chronic medical condition, as each classification was developed with its own
coding system. The ICD-10 and ICPC-2 codes used for this analysis are detailed in Supplementary
Tables 1-3.

153

Individuals with one or more high-risk chronic medical condition categories, regardless of whether they also had one or more moderate-risk conditions, were defined as being at high-risk for severe COVID-19. Individuals with one or more moderate-risk chronic medical condition categories and no high-risk chronic medical condition were defined as being at moderate-risk for severe COVID-19. Individuals without any listed chronic medical condition categories were defined as low-risk. Pregnancy was not a criterion for categorizing individuals into the high- or moderate-risk groups in all classifications.

160

161 Statistical Analysis

162 Data for the Netherlands and Norway were analyzed separately. Descriptive analyses were performed to 163 compare the respective national with the ECDC classification. The prevalence of high- and moderate-risk 164 medical condition categories, and the most frequent combinations of medical condition categories, were 165 shown in upset plots which visualize co-occurance of chronic medical condition categories in the

166 population.

167

168 We reported both absolute numbers and proportions of individuals by 10-year age groups, classified into

169 high-, moderate-, and low-risk groups for severe COVID-19. The discordance between the European and

170 each national classification was calculated as the proportion of the population with a different European

171 versus national risk status and visualized with matrix plots. Different medical risk classifications may use

172 different codes for the same chronic medical condition because they were formulated as such by the

173 classifications. The 95% confidence intervals (CI) of discordance and concordance proportions were

174 calculated using the Clopper-Pearson method¹².

175

To understand the factors related to discordance, we visualized the co-occurance of chronic medical condition categories in the discordant populations with upset plots. Since the Netherlands and Norway consider individuals above a certain age as high-risk for severe COVID-19, we assessed the discordance in three scenarios: 1) the entire population regardless of age, 2) individuals younger than 60 years of age, aligning with the Dutch schemes¹³, and 3) individuals younger than 65 years of age, aligning with the Norwegian schemes⁵.

182

A sensitivity analysis was conducted to assess the importance of the reference date by evaluating the
discordance for 1 January 2018, 1 January 2019, and 1 January 2021, instead of 1 January 2020.

186 Code Availability

187 The codes reproducing the results of this study are publicly available at

188 https://github.com/IWesterhof/COVID-19-risk-classifications.

189

190 Data Availability

- 191 The aggregated tables of counts generated and analyzed in this study are publicly available at
- 192 <u>https://github.com/IWesterhof/COVID-19-risk-classifications.</u>
- 193 Results are based on calculations by the authors using non-public microdata from Statistics Netherlands.
- 194 Under certain conditions, these microdata are accessible for statistical and scientific research. For further
- 195 information: microdata@cbs.nl.
- 196

197 Ethics

- 198 The analyses conducted with data from the Netherlands did not fall under the scope of the Dutch Medical
- 199 Research Involving Human Subjects Act (WMO) and, therefore, did not require approval from an
- 200 accredited ethics committee in the Netherlands. For the analyses conducted with data from Norway, the
- 201 Regional Committee for Medical and Health Ethics of South/East Norway (no. 285687) approved the
- study. The Norwegian Data Protection Services for research and the University of Oslo approved the Data
- 203 Protection Impact Assessment DPIA (no. 341884).
- 204

205 Role of the funding source

- 206 The funders of the study had no role in study design, data collection, data analysis, data interpretation, or
- writing of the report. The corresponding author had full access to all the data in the study and had final
- 208 responsibility for the decision to submit for publication.

209

210 Results

- 211 The Dutch cohort contained records of 17.4 million individuals (median age 42, interquartile range (IQR)
- 212 22-60), while the Norwegian cohort contained records of 5.6 million individuals (median age 39, IQR 21-

213 57).

214

215 Comparison of risk classifications for severe COVID-19

216 Chronic medical condition categories included in the European, Dutch, and Norwegian risk classifications 217 and their respective risk groups for severe COVID-19 are shown in Table 1. Several chronic medical 218 condition categories were consistently considered high-risk (e.g., cancer, immunodeficiency, and organ 219 transplants) and moderate-risk (e.g., dementia) in the European and national classifications. There was 220 some variability in the risk classifications of other conditions. Obesity was considered high-risk in the 221 European classification but moderate-risk in both national classifications; lung disease, heart disease, and 222 diabetes mellitus were considered high-risk in the European classification but moderate-risk in both 223 national classifications. Hypertension was only listed in the European classification. Down syndrome and 224 neurological disorders with impaired breathing were not included in the European classification but were 225 considered high-risk in both national classifications.

226

234

227 Classification of the general population by risk for severe COVID-19

Based on the national classifications, the most prevalent chronic medical condition categories in the Netherlands were lung disease, followed by cardiovascular disease, reduced immunity, and neurological/muscular disorder; all classified as moderate-risk (Figure 1 A). In Norway, the most prevalent conditions were cardiovascular disease, lung disease, and diabetes mellitus; these were also classified as moderaterisk (Figure 1 B). Based on the European classification, the most prevalent chronic medical condition categories in the Netherlands were cardiovascular disease, hypertension, and cancer, and in Norway

cardiovascular disease, diabetes mellitus, and cancer; all classified as high-risk (Figure 1 C-D).

medRxiv preprint doi: https://doi.org/10.1101/2024.09.06.24313189; this version posted September 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

235 Differences in the prevalence between classifications arise from variations in the diagnosis codes to define 236 a specific medical risk condition. For example, in the Netherlands, 0.54% of the population was classified 237 as having cancer using the national classification, compared to 2.0% using the European classification 238 because this classification included seven additional ICD-10 codes (Supplementary Tables 1-2). In 239 Norway, 2.3% of the population was classified as having cancer using the national classification compared 240 to 2.1% using the European classification due to differences in included codes. 241 242 In both countries and across all classifications, most individuals under 80 years of age were assigned low-243 risk for developing severe COVID-19 (Figure 2). Among children and adolescents (under 20 years old), 244 92.8% were classified as low-risk, 6.9% as moderate-risk, and 0.3% as high-risk, according to national 245 schemes, while this was 98.5%, 0.4%, and 1.2%, respectively, according to the European classification. In 246 Norway, the national classification identified 98.5% as low-risk, 0.4% as moderate-risk, and 1.2% as high-247 risk, while this was 96.4%, 0.5%, and 3.1%, respectively, according to the European classification. In both 248 countries and across all classifications, the percentage of individuals in moderate- and high-risk groups

249 increased with age, reaching 41.1% and 53.6% for those over 80 years in the national classifications, and

250 41.8% and 37.7% in the European classifications in the Netherlands and Norway, respectively.

251

252 Discordance between risk classifications and the related factors

253 In the Netherlands and Norway, risk classification differed for 12.0% and 13.8% of the general population, 254 respectively, between the national and the European classification schemes (Figure 3 A-B). The European 255 classification assigned more people as high-risk (9% in the Netherlands, 9.2% in Norway) compared to 256 national classifications (1.5% and 3.0%, respectively). Conversely, the national classifications identified 257 more people as moderate-risk (11.3% and 12.7%, respectively) than the European classification (1.0% and 258 1.3%, respectively). According to the national classifications, 87.2% of the population in the Netherlands 259 and 84.4% in Norway were classified as low-risk. These percentages were slightly higher using the 260 European classification (90.1% and 89.5%, respectively). Discordance was higher in elderly because the 261 number of individuals with one or more medical risk conditions was higher than in younger age groups 262 (Figure 2; Figure 3 C-F).

263 Figure 4 shows the chronic medical condition categories in individuals who were classified differently by 264 the European and respective national classification schemes (the discordant population). In the discordant 265 population in the Netherlands, 23.5% had neurological/muscular disorders, 23.8% reduced immunity, and 266 13.6% kidney disease according to the national classification (Figure 4A). In the discordant population in 267 Norway, 6.7% had reduced immunity, and 2.3% neurological/muscular disorders, classified as moderate-268 and high-risk, respectively (Figure 4B). None of the discordant individuals in the Netherlands had cancer, 269 while 0.6% did in Norway, explained by differences in ICD-10 and ICPC-2 coding practices between the 270 European and Norwegian classifications. On the contrary, the European classification included chronic 271 medical condition categories that were not included in the national classifications. In the Netherlands,

examples were hypertension and kidney disease with prevalences of 25.5% and 6.3% in the discordant

273 population. According to the European classification, 11.7% of the discordant Dutch population had cancer

in contrast to none according to the national classification, as the European classification encompassed

additional ICD-10 codes for cancer. In Norway, 8.2% of the discordant population had hypertension and

276 3.6% had kidney disease according to European schemes, but not included in national schemes. Unlike

277 Norway, none of the discordant individuals in the Netherlands were classified as overweight/obese or

diabetic based on the European classification.

279

280 In the Netherlands, the most common chronic medical condition categories varied by age group 281 (Supplementary Figures 1-2). In those younger than 60 or 65, lung disease was the most prevalent 282 condition, followed by neurological/-muscular disorder and cardiovascular disease. In Norway, the 283 national classification showed no differences between all ages and individuals younger than 65 and 60 284 years of age in most pronounced chronic conditions. In the Netherlands, based on the European 285 classification there was no change in the order of most prominent conditions contributing to discordance in 286 the population aged below 60 years compared to all ages. In contrast, for those aged below 65 years, the 287 most prevalent conditions were cardiovascular disease, diabetes mellitus, and lung disease, but not 288 hypertension and cancer.

290 Sensitivity analyses

291 No meaningful differences in discordance percentages were observed when using different reference dates

to define the study populations (data not shown).

293

294 Discussion

295 In this multi-country, nationwide registry-linkage study, we compared the respective national with the 296 European medical risk classification for severe COVID-19, and classified the populations of the 297 Netherlands and Norway according to this risk, across different age groups. Our findings revealed 298 substantial differences between these risk classifications, with the European classification scheme 299 assigning a broader range of chronic medical condition categories to the high-risk category than the two 300 national classifications. Consequently, a larger proportion of the population is classified as high-risk when 301 using the European classification compared to the national classifications. Conversely, a larger proportion 302 of the population is classified as moderate-risk when using the respective national classifications compared 303 to the European classification.

304

305 These discrepancies may have implications for COVID-19 vaccination programs, which prioritize specific 306 risk populations. Although primarily designed for research focusing on COVID-19 vaccine effectiveness 307 and enhancing SARI surveillance in Europe, the European protocols have influenced public health policy in the past, as demonstrated, for example, with influenza vaccination strategies¹⁴. Therefore, the European 308 309 classification for severe COVID-19 could remain relevant for broader public health decisions and policy. 310 Our comparative analysis suggests that using the European classification, 9.0% of the population in the 311 Netherlands and 9.2% of the population in Norway are high-risk due to chronic medical condition 312 categories and should be vaccinated, while these percentages are only 1.5% and 3.0%, respectively, when 313 using the national classifications. Vaccination programs that prioritize both moderate- and high-risk 314 groups, the European classification would result in 10.0% of the Dutch population and 10.5% of the 315 Norwegian population having to be vaccinated, compared to 12.8% and 13.7%, respectively, if using the 316 respective national classifications. Moreover, chronic medical condition categories are defined based on

317 different ICD-10 and ICPC-2 codes in the three classifications, resulting in differences in prevalence of 318 individual medical risk categories across classifications. Therefore, the choice between the European or 319 national classifications may have important consequences for vaccination prioritization and coverage, 320 potentially influencing the impact of vaccination campaigns in preventing severe COVID-19. 321 322 The dominant medical condition categories generating the discordance in risk status were lung and 323 cardiovascular disease in both Norway and the Netherlands, neurological disorders in the Netherlands, and 324 diabetes in Norway. Hypertension was one of the most pronounced discordant chronic condition categories 325 between classifications. According to the European classification, but not to the national ones, 326 hypertension was considered a high-risk disorder for severe COVID-19, and its prevalence estimate was 327 3.5% in the Netherlands and 1.4% in Norway. Several studies have indicated that hypertension was not an independent predictor of severe COVID-19^{15,16}. Therefore, the high-risk population might be 328 329 overestimated in the European classification. Lung disease, cardiovascular disease, and diabetes mellitus 330 were also among the most pronounced medical condition categories leading to discordance, which were 331 diagnosed in 1.7-4.6% of the population according to the national and European classifications. These 332 conditions were classified as moderate-risk in the national classifications but as high-risk in the European 333 classification. Although multiple studies have shown an increased risk of severe COVID-19 in individuals 334 with these medical condition categories^{17–19}, it is unknown whether they should be part of the high- or 335 moderate-risk group. Interestingly, the European classification does not include Down syndrome and 336 neurological/-muscular disorder as risk factors for severe COVID-19, while the national classifications 337 consider them as moderate- or high-risk chronic conditions. Several studies have demonstrated an increased risk of COVID-19 hospitalization and death among individuals with Down syndrome^{20,21} and 338 339 multiple sclerosis^{22,23}. This supports the need to assess the discordant conditions in relation to severe 340 COVID-19 to ensure vaccination prioritization and coverage of individuals at high-risk. 341

342 Our study has several limitations. There is a potential underestimation of the population with high- and

343 moderate-risk for severe COVID-19 in the Netherlands. The detection of chronic medical condition

344 categories in the Netherlands relied solely on ICD-10 codes from hospital discharge data. Individuals

345 without recent hospital admission may be missed, as hospital data might not capture those whose

346 conditions are managed in primary care. Consequently, there is a potential underestimation of the number 347 of individuals at moderate- and high-risk. Conversely, the analyses conducted for the population in 348 Norway, based on diagnostic records from both outpatient and inpatient specialist care, as well as from 349 primary care, were less susceptible to this bias. Another limitation is the absence of ICD-10 codes for 350 asplenia in the Norwegian registries. However, since asplenia is a very rare condition, with 0.44 surgical 351 asplenia per 100,000 person-years in Norway, it is unlikely to affect our overall conclusions²⁴. 352 353 Future research should aim to establish a consensus on which chronic medical condition categories are 354 universally recognized as conferring moderate- and high-risk for severe COVID-19. We propose a 355 matched multi-country cohort study to estimate the risk of hospitalization and death due to COVID-19 in 356 individuals with and without specific chronic conditions, accounting for confounders like age, vaccination 357 status, and variants. This research will help decide which classification best captures the population most at 358 risk. Moreover, mathematical modeling studies can help to understand the impact of different risk classifications and optimal vaccination strategies 25-28. Incorporating risk stratification into modeling 359

360 studies has the potential to design more effective strategies, a consideration often overlooked in current

361 research efforts. Furthermore, exploring emerging data sources and digital health technologies could

362 improve the identification and monitoring of moderate- and high-risk populations.

363

364 Conclusion

There are substantial differences between the European and the respective national medical risk classifications for severe COVID-19 based on pre-existing chronic medical condition categories, which may have important implications for vaccination strategies. The European classification suggests that a larger proportion of the population is at high-risk for severe COVID-19 and may require vaccination. The difference in classification is most pronounced for chronic medical condition categories belonging to the categories of cardiovascular disease, lung disease, and diabetes mellitus. Further research should identify to what extent the discordant chronic conditions are associated with severe COVID-19 risk.

373

374 Author Contributions

- 375 Conceptualization: I Westerhof, G Rozhnova. Data management: I Westerhof, A de Boer. Methodology: I
- 376 Westerhof, A de Boer, G Rozhnova. Investigation: I Westerhof, A de Boer. Formal analysis: I Westerhof,
- 377 A de Boer. Visualization: I Westerhof. Writing-original draft: I Westerhof, A de Boer, G Rozhnova.
- 378 Writing—review and editing: I Westerhof, A de Boer, A Lupattelli, I Slurink, O Boldea, HME Nordeng,
- 379 JR Bosdriesz, F Pijpers, M Schim van der Loeff, M Knol, JHHM van de Wijgert, P Bruijning, and G
- 380 Rozhnova.

381

382 Declaration of interests

- 383 We declare no competing interests.
- 384

385 Acknowledgments

386 We are grateful to all the participating families in the Netherlands and Norway who are part of the health

387 registries and made this research possible. GR, IW, AdB, and OB were supported by the ZonMw project

388 (10430362220002). GR was supported by Fundação para a Ciência e a Tecnologia project

389 2022.01448.PTDC, DOI 10.54499/2022.01448.PTDC. GR, IW, AL, and PB were supported by the

390 VERDI project (101045989), funded by the European Union. Views and opinions expressed are however

391 those of the author(s) only and do not necessarily reflect those of the European Union or the Health and

392 Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible

393 for them. IW was supported by the scholarship program iAPOGEE "International Alliance for

394 PharmacoGenetic Epidemiology Excellence" at the University of Oslo, Norway. Data acquisition of the

395 Norwegian data in this study was funded by HN's EU-COVID-19 project, funded by the Norwegian

Research Council's COVID-19 Emergency Call (project no. 31270). The work on the Norwegian data was

397 performed on the TSD (Tjeneste for Sensitive Data) facilities, owned by the University of Oslo, operated

398 and developed by the TSD service group at the University of Oslo, IT-Department (USIT) (tsd-

399 <u>drift@usit.uio.no</u>).

All rights reserved. No reuse allowed without permission.

401 References \rightarrow max 30 references

402 1 World Health Organization. Global Covid-19 Vaccination Strategy in a Changing 403 World July 2022 update. 2022 https://www.who.int/publications/m/item/global-covid-404 19-vaccination-strategy-in-a-changing-world--july-2022-update (accessed April 30, 405 2024). 406 2 Antos A, Kwong ML, Balmorez T, Villanueva A, Murakami S. Unusually High Risks 407 of COVID-19 Mortality with Age-Related Comorbidities: An Adjusted Meta-Analysis 408 Method to Improve the Risk Assessment of Mortality Using the Comorbid Mortality 409 Data. Infect Dis Rep 2021; 13: 700–11. Zhang J, Dong X, Liu G, Gao Y. Risk and Protective Factors for COVID-19 410 3 Morbidity, Severity, and Mortality. Clin Rev Allergy Immunol 2022; 64: 90-107. 411 412 4 Gezondheidsraad. Adviesnota Vaststelling volwassen medische risicogroepen COVID-413 19-vaccinatiecampagne. 2023 https://lci.rivm.nl/sites/default/files/bestanden/COVID-414 19/COVID-19-vaccinatie/Adviesnota-vaststelling-volwassen-medische-risicogroepen-415 covid-19-vaccinatiecampagne.pdf (accessed April 1, 2024). 416 5 Norwegian Institute of Public Health. Coronavirus vaccine. ups-and-417 childrenadolescents-with-underlying-conditions. 2023. 418 https://www.fhi.no/en/id/corona/coronavirus-immunisation-programme/coronavirus-419 vaccine (accessed April 17, 2024). 420 European Centre for Disease Prevention and Control. Core protocol for ECDC studies 6 421 of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute 422 Respiratory Infection, laboratory-confirmed with SARS-CoV-2 or with seasonal 423 influenza - Version 3.0. 2024 https://www.ecdc.europa.eu/en/publications-data/core-424 protocol-ecdc-studies-covid-19-vaccine-effectiveness-3 (accessed March 10, 2024). 425 7 European Centre for Disease Prevention and Control. Core protocol for ECDC studies 426 of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute 427 Respiratory Infection laboratory-confirmed with SARS-CoV-2, version 1.0. 428 Stockholm, 2021. 429 8 Norwegian Institute of Public Health. Coronavirus vaccine. 2020. 430 https://www.fhi.no/en/id/corona/coronavirus-immunisation-programme/coronavirus-431 vaccine (accessed Sept 1, 2022). Gezondheidsraad. Advies Strategieën voor COVID-19-vaccinatie. 2020 432 9 433 https://www.gezondheidsraad.nl/documenten/adviezen/2020/11/19/strategieen-voor-434 covid-19-vaccinatie (accessed April 1, 2024). 435 10 World Health Organization. International Statistical Classification of Diseases Related 436 Health Problems 10th Revision Geneva. https://icd.who.int/browse10/2019/en. 2019. 437 11 World Health Organization. International Classification of primary care, 2nd edition 438 (ICPC-2). https://www.who.int/standards/classifications/other-439 classifications/international-classification-of-primary-care. 2024. 440 Clopper CJ, Pearson ES. The Use of Confidence or Fiducial Limits Illustrated in the 12 441 Case of the Binomial. Biometrika 1934; 26: 404. Rijksinstituut voor Volksgezondheid en Milieu. COVID-19 vaccination. 2024; 442 13 443 published online March. https://www.rivm.nl/en/coronavirus-covid-19/vaccination 444 (accessed April 22, 2024). Mereckiene J, Cotter S, Nicoll A, et al. Seasonal influenza immunisation in Europe. 445 14 446 Overview of recommendations and vaccination coverage for three seasons: pre-447 pandemic (2008/09), pandemic (2009/10) and post-pandemic (2010/11). 448 Eurosurveillance 2014; 19. DOI:10.2807/1560-7917.ES2014.19.16.20780.

	perpetation
All rights recorded	No rouce allowed without permission
All lights reserved.	
0	

449 450 451	15	D'Elia L, Giaquinto A, Zarrella AF, <i>et al.</i> Hypertension and mortality in SARS-COV-2 infection: A meta-analysis of observational studies after 2 years of pandemic. <i>Eur J</i> Intern Med 2023: 108 : 28–36
452	16	Fresán U. Guevara M. Trobaio-Sanmartín C. Burgui C. Ezpeleta C. Castilla I.
453	10	Hypertension and Related Comorbidities as Potential Risk Factors for COVID-19
454		Hospitalization and Severity: A Prospective Population-Based Cohort Study. J Clin
455		<i>Med</i> 2021: 10 : 1194.
456	17	Ge E, Li Y, Wu S, Candido E, Wei X. Association of pre-existing comorbidities with
457		mortality and disease severity among 167,500 individuals with COVID-19 in Canada:
458		A population-based cohort study. PLoS One 2021; 16: e0258154.
459	18	Wee LE, Tan JYJ, Chiew CJ, et al. A Nationwide Cohort Study of Delta and Omicron
460		SARS-CoV-2 Outcomes in Vaccinated Individuals With Chronic Lung Disease. Chest
461		2024; published online June. DOI:10.1016/j.chest.2024.05.017.
462	19	Rainer L, Bachner F, Eglau K, Ostermann H, Siebert U, Zuba M. Comorbidities and
463		COVID-19 hospitalization, ICU admission and hospital mortality in Austria. Wien Klin
464		Wochenschr 2022; 134: 856–67.
465	20	Bedston S, Almaghrabi F, Patterson L, et al. Risk of severe COVID-19 outcomes after
466		autumn 2022 COVID-19 booster vaccinations: a pooled analysis of national
467		prospective cohort studies involving 7.4 million adults in England, Northern Ireland,
468		Scotland and Wales. The Lancet Regional Health - Europe 2024; 37: 100816.
469	21	Semenzato L, Botton J, Drouin J, et al. Chronic diseases, health conditions and risk of
470		COVID-19-related hospitalization and in-hospital mortality during the first wave of the
471		epidemic in France: a cohort study of 66 million people. The Lancet Regional Health -
472		<i>Europe</i> 2021; 8 : 100158.
473	22	Prosperini L, Tortorella C, Haggiag S, Ruggieri S, Galgani S, Gasperini C. Increased
474		risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational
475		studies. J Neurol 2022; 269 : 1114–20.
476	23	Moreno-Torres I, Meca Lallana V, Costa-Frossard L, et al. Risk and outcomes of
477		COVID-19 in patients with multiple sclerosis. <i>Eur J Neurol</i> 2021; 28 : 3712–21.
478	24	Orangzeb S, Watle SV, Caugant DA. Adherence to vaccination guidelines of patients
479	~ ~	with complete splenectomy in Norway, 2008–2020. Vaccine 2023; 41: 4579–85.
480	25	Béraud G. Mathematical models and vaccination strategies. <i>Vaccine</i> 2018; 36 : 5366–
481	26	72.
482	26	Bubar KM, Reinholt K, Kissler SM, <i>et al.</i> Model-informed COVID-19 vaccine
483	07	prioritization strategies by age and serostatus. <i>Science (19/9)</i> 2021; 3 /1: 916–21.
484	27	Viana J, van Dorp CH, Nunes A, <i>et al.</i> Controlling the pandemic during the SARS-
485	20	CoV-2 vaccination rollout. Nat Commun 2021; 12: 36/4.
486	28	Matrajt L, Eaton J, Leung I, Brown EK. Vaccine optimization for COVID-19: Who to
48/		vaccinate first? Sci Adv 2021; 1. DOI:10.1126/sciadv.ab113/4.
400		

- 490 Table 1. Comparison of European and national risk classifications for severe COVID-19. Chronic
- 491 medical condition categories based on ICD-10 and ICPC-2 codes (see Supplementary Tables 1-3) and
- 492 their respective risk groups for severe COVID-19 are shown. Different medical risk classifications may use
- 493 different codes for the same chronic medical condition.

Chronic medical condition categories	Chronic medical condition categories Classification		า
	European	Dutch	Norwegian
Cancer (solid organ and haematological)			
Immunodeficiency			
Organ transplant			
Overweight and obesity			
Lung disease			
Cardiovascular disease			
Diabetes mellitus			
Hypertension			
Kidney disease dialysis required			
Anaemia			
Kidney disease			
Liver disease/cirrhosis			
Neurological disorder (without impaired breathing)			
Dementia			
Tuberculosis			
Stroke			
Asplenia			
Rheumatologic disease			
Sickle cell disease			
Down syndrome			
Neurological disorder with impaired breathing			
Reduced immunity			
HIV infection			
Cochlear implants			
Risk due to chronic medical conditions = High = Mod	erate	= low	

494

496	Figure 1. Chronic conditions in the general population. A-B) National and C-D) European medical risk
497	classification for severe COVID-19. In all classifications, chronic medical condition categories were
498	assigned if registered in the past six months prior to 1 January 2020, except for cancer which was assigned
499	if registered in the prior five years. The left bars show the number and proportion of each chronic medical
500	condition categories in the population. Orange bars indicate the high-risk chronic conditions according to
501	the classification, while blue bars indicate moderate-risk chronic conditions. The dots represent the
502	presence of one or more chronic medical condition categories in an individual, with the upper bars
503	showing the combinations that occur in at least 1% of the population with chronic conditions.
504	
505	Figure 2. Classification of the general population by risk for severe COVID-19. Population shown as
506	absolute numbers (top) and proportions (bottom) classified by age and risk for severe COVID-19 due to
507	chronic medical condition categories in the A-B) national and C-D) European classifications.
508	
509	Figure 3. Discordance and concordance in assigning risk status to individuals between the European
510	and national classifications. General population of A-B) all ages, C-D) ages below 65 years, and E-F)
511	ages below 60 years. The discordance between the European and each national classification was
512	calculated as the proportion of the general populations with a different risk status (off-diagonal elements).
513	Concordance is the proportion of the population classified into the same risk group (diagonal elements).
514	Since every individual belongs to one of the risk groups, the elements of the matrix plots add up to 100%.
515	
516	Figure 4. Chronic conditions in the discordant population. A-B) National and C-D) European medical
517	risk classification for severe COVID-19. In all classifications, chronic medical condition categories were
518	those that had been registered in the past six months prior to 1 January 2020, except for cancer which was
519	included as a chronic medical condition if registered in the past five years preceding 1 January, 2020. The
520	dots represent the presence of one or more chronic medical condition categories. The left bars show the
521	number and proportion of each chronic medical condition categories in the population. Orange bars
522	indicate the high-risk chronic conditions according to the classification, while blue bars indicate moderate-
523	risk chronic conditions. The upper bars show the combinations of chronic conditions that occur in at least
524	1% of the population with chronic conditions.

<u>Risk group</u>	Disease category	ICD-10 codes
High	Cardiovascular disease	A52.01, B37.6, B58.81, I05-09, I11, I13, I20-25,
U		I26.9, I27, I30-51, I97.0-97.1, R00.1, T81.718A,
		T81.72XA, T82.817A, T82.818A, Q20-24, Q25.1-
		25.2, Q26.0-26.1, Q26.8, Q87.4, R01.1, R02
High	Cancer	C00-96
High	Diabetes mellitus	E10-11
High	Hypertension	110, 115, 115.1, 115.2, 115.8, 127.0, 197.3
High	Immunodeficiency or organ	B20, D80-84, D89.8-89.9, Z21, Z94
	transplant	
High	Lung disease	A15, J18.2, J40-47, J60-94, J96, J99, M34.81,
		M05.10
High	Obesity	E66.01, E66.2, E66.9
Moderate	Anemia	D50-64
Moderate	Asplenia (not available in	Q89.01, Q20.6, Z90.81
	Norwegian registries)	
Moderate	Dementia	F01, F03, F05, G30-31, G91, G94
Moderate	Kidney disease	M10.30, N00-19, N20.0, N28.9
Moderate	Liver disease	K70, K72-74, K75.4, K76.9
Moderate	Neurological disorder	G70, G73.7
Moderate	Rheumatologic diseases	M30-34, M35.5, M35.8-35.9, M05-06, M08,
		M12.00
Moderate	Stroke	G93, I67.83, I69
Moderate	Tuberculosis	A15-19

Supplementary Table 1 European risk classification, ICD-10 codes⁶.

Supplementary Table 2 Dutch risk classification, ICD-10 codes⁴.

Risk group	Disease category	ICD-10 codes
High	Cancer	C00-C75, C81-86, C88, C90-96.
High	Down syndrome	Q90
High	Immunodeficiency disease	D800.0, D81, D830.0-830.2, D83.8-83.9
High	Kidney failure (dialysis	N18.5
	required)	
High	Neurological disorders	G00-G99 in combination with R06
	compromising respiration	
High	Organ transplantation	Z94.0-94.4, Z94.8
High	Overweight and obesity	E66
High	Sickle cell disease	D57.0-57.2
Moderate	Cardiovascular disease	C38, C49.3, D511, D213, I00-2, I05-9, I20-3, I30-
		52, Q20-8, P29.3, Z950
Moderate	Chronic kidney disease	N00-N39
Moderate	Cochlear implants	Z96.2
Moderate	Dementia	F00-01, F03, F10.6
Moderate	Diabetes mellitus	E10-14
Moderate	HIV	B20-24
Moderate	Lung disease	A15-19, C30-34, C39, D86, E84, J00-99, Q30-34
Moderate	Neurological disorders	G00-99, I60-69
Moderate	Reduced immunity	B17.0, B18.0-18.1, C81-96, D50-89, E24-27, K50-
		51, K70-77, M0-14, M353, N0-39.

Dick group	Disease estagemy	ICD 10 and as	
KISK group	Disease category	ICD-10 codes	<u>ICFC-2</u>
			codes
High	Cancer	C0-7, C80-96, D45, D47	-
High	Down Syndrome	Q90	-
High	Immunodefiency disease	D80-84	-
High	Organ transplantation	Z94.0-94.4, Z94.8	-
High	Neurological disorders	G1, G20-21, G23-24, G40.5,	-
_	_	G61.0, G70-73, F84.0-84.1,	
		Q05.0-05.6, G80.0, G80.2-80.3	
High	Kidney failure	N18.3-18.5	-
High	Liver disease	K70.4, K72	-
Moderate	Diabetes mellitus	E10-14	T89-90
Moderate	Lung disease	E84, J41-J47, J84, J98	R95-96
Moderate	Overweight and obesity	E66	T82
Moderate	Cardiovascular disease	105-09, 12, 131-32, 134-37, 139-43,	K74-78, K82-
		146, 148-50	83, K87
Moderate	Stroke	160-64, 169.1-69.4, 169.8, 169.0	K90-91
Moderate	Dementia	F0, G30-31	P70
Moderate	Reduced immunity	G35, M05-09, M13-14, K50-51	-

Supplementary Table 3 Norwegian risk classification, ICD-10 and ICPC-2 codes⁵.

Supplementary Figure 1. Chronic conditions in the discordant population aged <60 years. A-B)

National and **C-D**) European medical risk classification for severe COVID-19. In all classifications, chronic medical condition categories were those that had been registered in the past six months prior to 1 January 2020, except for cancer which was included as a chronic medical condition if registered in the past five years preceding 1 January, 2020. The dots represent the presence of one or more chronic medical condition categories. The left bars show the number and proportion of each chronic medical condition categories in the population. Orange bars indicate the high-risk chronic conditions according to the classification, while blue bars indicate moderate-risk chronic conditions. The upper bars show the combinations of chronic conditions that occur in at least 1% of the population with chronic conditions.

Supplementary Figure 2. Chronic conditions in the discordant population aged <65 years. A-B)

National and **C-D**) European medical risk classification for severe COVID-19. In all classifications, chronic medical condition categories were those that had been registered in the past six months prior to 1 January 2020, except for cancer which was included as a chronic medical condition if registered in the past five years preceding 1 January 2020. The dots represent the presence of one or more chronic medical condition categories. The left bars show the number and proportion of each chronic medical condition categories in the population. Orange bars indicate the high-risk chronic conditions according to the classification, while blue bars indicate moderate-risk chronic conditions. The upper bars show the combinations of chronic conditions that occur in at least 1% of the population with chronic conditions.





Population



С

Population

Norway, European classification





Discordance = 12.0% (95% CI 12.0–12.1%) Concordance = 88.0% (95% CI 87.9-88.0%) Discordance = 13.8% (95% CI 13.8–13.9%) Concordance = 86.2% (95% CI 86.1-86.2%) 9.2%

1.3%

89.5%

100%

Total

С		The Netherlands, aged <65						Norway, aged <65			
_	High	- 0.8%	2.8%	0.7%	4.4%		_ High -	1.1%	3.6%	0.5%	5.3% -
catior	Voderate	- 0.0%	0.7%	0.0%	0.7%	bean catior	Moderate ·	0.1%	0.4%	0.5%	1.0% -
Europ lassifi	Low	- 0.2%	4.2%	90.5%	94.9%	Europ lassifi	Low	0.3%	4.4%	89.1%	93.8% -
U	Total	- 1.1%	7.7%	91.3%	100%	- · ·	Total	1.5%	8.4%	90.1%	100% -
		High	Moderate National cl	Low	Total			High	Moderate National cla	Low	Total

Discordance = 8.0% (95% CI 8.0-8.0%) Concordance = 92.0% (95% CI 92.0-92.0%)

Discordance = 9.4% (95% CI 9.4–9.4%) Concordance = 90.6% (95% CI 90.6-90.6%)



Discordance = 7.3% (95%Cl 7.2-7.3%) Concordance = 92.7% (95% Cl 92.7-92.8%) Discordance = 8.4% (95% CI 8.4-8.5%) Concordance = 91.6% (95% CI 91.5-91.6%)

